王天双,肖刚,李林,张俭,张德新,陆莹. Lingo-1及其相关传导通路在神经系统修复中的研究进展[J]. 中国急救医学, 2018, 38(7): 636-640.
Wang Tian-shuang, Xiao Gang, Li Lin, Zhang Jian, Zhang De-xin, Lu Ying. Research progresses on Lingo-1 and its related conductive pathway for nervous system repair. Chinese Journal of Critical Care Medicine, 2018, 38(7): 636-640.
[1]Mi S, Lee X, Shao Z, et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex[J]. Nat Neurosci, 2004,7(3):221-228.
[2]Mi S, Sandrock A, Miller RH. LINGO-1 and its role in CNS repair[J]. Int J Biochem Cell Biol, 2008, 40(10):1971-1978.
[3]Haines BP, Rigby PW. Expression of the Lingo/LERN gene familyduring mouse embryogenesis[J]. Gene Expr Patterns, 2008, 8(2):79-86.
[4]Carim-Todd L, Escarceller M, Estivill X, et al. LRRN6A/LERN1(leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex[J]. Eur J Neurosci, 2003, 18(12):3167-3182.
[5]Mi s, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes[J]. Nat Neurosci, 2005, 8(6):745-751.
[6]Lee X, Yang Z, Shao Z, et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination[J]. J Neurosci, 2007, 27(1):220-225.
[7]Mi S, Hu B, Hahm k, et al. LINGO-1 antagonist pomotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis[J]. Nat Med, 2007, 13(10):1228-1233.
[8]Ji B, Li M, Wu WT, et al. Lingo-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury[J]. Mol Cell Neurosci, 2006, 33(3):311-320.
[9]Liang C, Chen BH, Teng SL, et al. Effects of limb ischemic postconditioning on expression of LINGO-1 in brain and neural function after focal cerebral infarction in rats[J]. Chin J Pathophysiol, 2017, 33(3): 548-551.
[10]Zhang Y, Zhang YP, Pepinsky B, et al. Inhibitionof LINGO-1 promotes function recovery after experimental spinal cord demyelination[J]. Exp Neurol, 2015, 266: 68-73.
[11]Wang CJ, Qu CQ, Zhang J, et al. Lingo-1 inhibited by RNA interference promotes functional recovery of experimental autoimmune encephalomyelitis[J]. Anat Rec, 2014, 297(12): 2356-2363.
[12]Kwon HS, Nakaya N, Abu-Asab M, et al. Myocilin is involved in NgR1/Lingo-1-mediated oligodendrocyte differentiation and myelinationof the optic nerve[J]. J Neurosci, 2014, 34(16): 5539-5551.
[13]Fu QL, Hu B, Wu W, et al. Blocking LINGO-1 function promotes retinal ganglion cell survival following ocular hypertension and optic nerve transection[J]. Invest Ophthalmol Vis Sci, 2008, 49(3): 975-985.
[14]StorkO, Pape HC.Fear memory and the amygdala:insights from a molecular perspective[J]. Cell Tissue Res, 2002, 310(3):271-277.
[15]Inoue H, Lin L, Lee X, et al. Inhibition of the lecucine-rich repeat protein LINGO-1 enhances survival, structure,and function of dopaminergic neurons in Parkinson′s disease models[J]. Proc Natl Acad Sci USA, 2007, 104(36):14 430-14 435.
[16]Zhu HY, Guo HF, Hou HL, et al. Increase expression of the Nogo receptor in the hippocampus and its relation to the neuropathology in Alzheimer′s disease[J]. Hum Pathol, 2007, 38(3):426-434.
[17]Fung SJ, Webster MJ, Sivagnanasundaram S, et al. Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia[J]. Am J Psychiatry, 2010, 167(12):1479-1488.
[18]Jarrard LE. Retrograde amnesia and consolidation:anatomical and lesion considerations[J]. Hippocampus, 2001, 11(1):43-49.
[19]Hunt D, Mason MR, Campbell G, et al. Nogo receptor mRNA expression in intact and regenerating CNS neurons[J]. Mol Cell Neurosci, 2002, 20(4):537-552.
[20]Thompson HJ, Marklund N, LeBold DG, et al. Tissue sparing and functional recovery following experimental traumatic brain injury is provided by treatment with an anti-myelin-associated glycoprotein antibody[J]. Eur J Neurosci, 2006, 24(11):3063-3072.
[21]Rabizadeh S, Bredesen DE. Ten years on: mediation of cell death by the common neurotrophin receptor p75(NTR)[J]. Cytokine Growth Factor Rev, 2003, 14(3-4): 225-239.
[22]Barker PA. p75NTR is positively promiscuous: novel partners and new insights[J]. Neuron, 2004, 42(4): 529-533.
[23]von Schack D, Casademunt E, Schweigreiter R, et al. Complete ablation of the neurotrophin receptor p75NTR causes defects both in the nervous and the vascular system[J]. Nat Neurosci, 2001, 4(10): 977-978.
[24]Wang KC, Kim JA, Sivasankaran R, et al. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp[J]. Nature, 2002, 420(6911): 74-78.
[25]Shao Z, Browning JL, Lee X, et al. TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration[J]. Neuron, 2005, 45(3): 353-359.
[26]Park JB, Yiu G, Kaneko S, et al. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors[J]. Neuron, 2005, 45(3): 345-351.
[27]Satoh J, Tabunoki H, Yamamura T, et al. TROY and LINGO-1 expression in astrocytes and macrophages/microglia in multiple sclerosis lesions[J]. Neuropathol Appl Neurobiol, 2007, 33(1):99-107.
[28]Hanks SK, Quinn AM, Hunter T. The protein kinase family:conserved features and deduced phylogeny of the catalytic domains[J]. Science, 1988, 241(4861): 42-52.
[29]Choat KA, Kahle KT, Wilson FH, et al. WNK1, a kinase mutated in inherited hypertension with hyperkalemia, Localizes to diverse Cl-transporting epithelia[J]. Proc Natl Acad Sci USA, 2003, 100(2): 663-668.
[30]Zhang Z, Xu X, Zhang Y, et al. LINGO-1 interacts with WNK1 to regulate nogo-induced inhibition of neurite extension[J]. J Biol Chem, 2009, 284(23): 15 717-15 728.
[31]Zambrowicz BP, Abuin A, Ramirez-Solis R, et al. Wnk1 kinase deficiency lowers blood pressure in mice:agene-trap screen to identify potential targets for therapeutic intervention[J]. Proc Natl Acad Sci USA, 2003, 100(24): 14 109-14 114.
[32]Mistry M, Gillis J, Pavlidis P. Genome-wide expression profiling of schizophrenia using a large combined cohort[J]. Mol Psychiatry, 2012, 18(2): 215-225.
[33]Armstrong RC, Kim JG, Hudson LD. Expression of myelin transcription factor I (MyTI), a “zinc-finger”DNA-binding protein, in developing oligodendrocytes[J]. Glia, 1995, 14(4): 303-321.
[34]Bellefroid EJ, Bourguignon C, HollemannT, et al. X-MyT1,a Xenopus C2HC-type zinc finger protein with a regulatory function in neuronal differentiation[J]. Cell, 1996,87(7):1191-1202.
[35]Armstrong RC, Migneault A, Shegog ML, et al. High-grade human brain tumors exhibit increased expression of myelin transcription factor 1(MYT1), a zinc finger DNA-binding protein[J]. J Neuropathol Exp Neurol, 1997, 56(7): 772–781.
[36]Kim JG, Armstrong RC, v Agoston D, et al. Myelin transcription factor 1(Myt1) of the oligodendrocyte lineage, along with a closely related CCHC zinc finger, is expressed in developing neurons in the mammalian central nervous system[J]. J Neurosci Res, 1997, 50(2): 272-290.
[37]Llorens F, Gil V, Iraola S, et al. Developmental analysis of Lingo-1/Lern1 protein expression in the mouse brain: interaction of its intracellular domain with Myt1l[J]. Dev Neurobiol, 2008, 68(4): 521-541.
[38]Vana AC, Lucchinetti CF, Le TQ, et al. Myelin transcription factor1 (Myt1) expression in demyelinated lesions of rodent and human CNS[J]. Glia, 2007, 55(7): 687-697.
[39]Brunet A, Datta SR, Greenberg ME. Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway[J]. Curr Opin Neurobiol, 2001, 11(3): 297-305.
[40]Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive pathway map of epidermal growth factor receptor signaling[J]. Mol Syst Biol, 2005, 1∶〖KG-*2〗2005.
[41]Koprivica V, Cho KS, Park JB, et al. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans[J]. Science, 2005, 310(5745): 106-110.
[42]Jiang ZY, Zhou QL, Holik J, et al. Identification of WNK1 as a substrate of Akt/protein kinase B and a negative regulator of insulin-stimulated mitogenesis in 3T3-L1 cells[J]. J Biol Chem, 2005, 280(22): 21 622-21 628.
[43]Okumura E, Fukuhara T, Yoshida H, et al. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition[J]. Nat Cell Biol, 2002, 4(2): 111-116.
[44]Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair:from concept to the clinic[J]. CNS Drugs, 2013, 27(7): 493-503.
[45]Tran JQ, Rana J, Barkhof F, et al. Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033[J]. Neurol Neuroimmunol Neuroinflamm, 2014, 1(2): e18.